Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") filed a class action in the U.S. District Court for the Southern District of New York alleging violations ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Android version ...

However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...

Stifel projected that the 15-day sensor could enhance DexCom’s gross margin in 2026, potentially contributing to year-over-year EBITDA margin expansion. The firm acknowledged certain risks, including ...

Dexcom raised its sales expectations for 2025 amid expanding access to its glucose sensors for people with Type 2 diabetes. The company raised its revenue forecast to a range of $4.6 billion to about ...

The company’s sensor and other revenue, which represents 97% of total revenue, jumped 18% YoY to $1.12 billion, offsetting a 31% decline in hardware revenue. "During the quarter, Dexcom delivered ...

Medicare Part B typically covers continuous glucose monitors (CGMs) like the Dexcom G7, as they are Food and Drug Administration (FDA)-approved durable medical equipment items. To get a Dexcom G7 CGM ...

An interdisciplinary team of researchers from various Chinese universities have developed a miniature-sized continuous glucose monitoring system that works as effectively as market-leading systems.

The Stelo glucose monitor. [Image courtesy of Dexcom] Dexcom (Nasdaq:DXCM) Chair, President and CEO Kevin Sayer says that, in 2019, he gave a speech announcing the company’s first $1 billion year.